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Abstract 
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-
Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis 
and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant melanoma setting. 
Since angiogenesis is essential for primary tumour growth and the development of metastasis, anti-angiogenic agents are attractive 
potential therapeutic candidates for clinical trials in the adjuvant setting. Therefore, we initiated a phase II trial in resected high-risk 
cutaneous melanoma, assessing the efficacy of bevacizumab versus observation. 
In the interim safety data analysis, we demonstrate that bevacizumab is a safe therapy in the adjuvant melanoma setting with no 
apparent increase in the surgical complication rate after either primary tumour resection and/or loco-regional lymphadenectomy. 
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Introduction 
Many prospective randomised trials of adjuvant therapy, 
particularly using cytokine immunotherapies [1,2], have been 
performed in patients after resection of cutaneous melanoma. 
However, to date, no treatment has convincingly improved 
overall disease survival. 
Since angiogenesis is fundamental to the development and 
growth of malignant melanomas [3], this aspect of melanoma 
biology is an attractive candidate for therapeutic intervention. In 
vitro pre-clinical studies either using single-agent angiogenic 
inhibitors or in combination with growth factor pathway tyrosine 
kinase inhibitors (TKIs) have demonstrated cytocidal effects in 
melanoma and epithelial cancer cells [4,5]. 
Vascular endothelial growth factor (VEGF) isoforms are the 
most important pro-angiogenic ligands in tumour biology [6]. 
Based on pre-clinical studies, VEGF isoforms, particularly 
VEGF-A, are relevant targets in melanoma. 
Immunohistochemical studies suggest that VEGF-A is 
expressed in around two-thirds of primary melanomas [7], and 
high expression levels of VEGF-A are associated with vertical 
phase tumour growth and disease progression to both loco-
regional and distant sites [8]. Notably, loco-regional nodal 
metastasis seem to differentially express specific VEGF-A 
splice variants and express higher levels of VEGF121 and 
VEGF165 when compared to distant metastatic sites [8]. 
Bevacizumab (Avastin, F Hoffman-La Roche Ltd) is a 
recombinant humanized IgG1 monoclonal antibody to pan-
VEGF isoforms. To date, bevacizumab has been investigated in 
the metastatic first- and second-line settings for colorectal 
cancer [9,10], as well as anthracycline-refractory breast cancer 
[11] and in combination with interferon-alpha-2a in clear-cell 
renal cancer [12]. These studies have confirmed bevacizumab 
to have an acceptable toxicity profile, with fatigue, hypertension 
and proteinuria being the commonest toxicities. The results of a 
phase III trial investigating the utility and toxicity profile of 
bevacizumab in the adjuvant management of resected 
colorectal cancer, after systemic chemotherapy, is currently 
awaited [13]. This trial could also be informative as to whether 
bevacizumab increases the incidence of intermediate- to long-
term post-surgical complications, after adjuvant chemotherapy. 
A series of small phase II studies in metastatic melanoma 
suggests that bevacizumab also has activity in this disease [14]. 
Since angiogenesis is fundamental in the development of 
systemic metastasis, anti-angiogenic therapy after complete 
resection of cutaneous melanoma is therefore an attractive 
candidate for investigation. Therefore, at our cancer centre, we 
have initiated a phase III trial investigating bevacizumab versus 
observation in patients with fully resected high-risk cutaneous 
melanoma. 
 
Methods: AVAST-M trial design 
The UK AVAST-M Phase III Multi-Centre Prospective Clinical 
Trial, funded by Cancer Research UK, randomises melanoma 
patients at high risk of recurrence to receive bevacizumab 7.5 
mg/kg IV three-week administered for one year, or to standard 
observation. 
Overall survival will be compared in 1320 patients, to identify an 
8% difference in overall survival at five years (80% power, 5% 
significance) as the primary end point. 
 
Trial objectives 
Primary objective 
•  Overall survival  
Secondary objectives 
• Disease-free  interval 
•  Distant metastasis-free interval 
•  Safety and toxicity 
•  Quality of life (QoL)  
Tertiary objectives 
•  Identification of markers of angiogenesis in peripheral 
blood and tumour tissue 
 
Trial population 
Main inclusion criteria 
•  Patients with histological confirmation of completely 
resected American Joint Commission on Cancer 
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(AJCC) stage IIB (T3bN0M0 and T4aN0M0), IIC 
(T4bN0M0) and III (TxN1-3M0) cutaneous melanoma. 
•  Patients may or may not have undergone sentinel 
lymph node dissection and/or elective lymph node 
dissection. 
•  Patients must be randomised within 12 weeks of 
completing surgery (wide local excision or 
lymphadenectomy). 
Main exclusion criteria 
•  Any evidence of distant or non-regional lymph node 
metastases. 
•  Evidence of CNS metastases, even if previously 
treated. 
•  Incomplete surgical resection of the disease. 
•  Prior chemotherapy, immunotherapy or hormonal 
therapy for melanoma within 12 weeks of 
randomisation. 
•  History or evidence of any disorder with increased risk 
of bleeding. 
•  Uncontrolled hypertension. 
Main trial assessments 
•  CT/MRI scans of head, chest, abdomen and pelvis 
(only at baseline and subsequently if clinically 
indicated). 
• Chest  x-rays. 
• Protein  urinalysis. 
•  Haematology and clinical chemistry tests. 
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• Quality-of-life  EORTC  QLQC30 questionnaire. 
•  Blood and tissue for biomarker studies. 
 
Current status of AVAST-M 
The AVAST-M trial opened to recruitment in the UK in July 
2007. 
 
As of 31 July 2008, 156 patients had been recruited: 76 on 
treatment arm, 80 on observation. To date, nine patients have 
been withdrawn from treatment: three due to distant recurrence, 
two due to toxicity, one due to local recurrence and three 
patients withdrew consent. There have been no patient deaths 
to 31 July 2008. 
 
Patient recruitment of AVAST-M 
 
 
Toxicities of AVAST-M 
Six serious adverse episodes (SAEs), including one suspected 
unexpected serious adverse reaction (SUSAR), have been 
reported to date; two for the observation arm and four for the 
treatment arm. 
In the observation arm, one patient had a grade 3 skin infection 
and was hospitalized for antibiotic therapy, and another patient 
had spinal cord compression caused by disseminated disease. 
In the treatment arm, one patient who was previously 
normotensive, had bevacizumab-induced grade 3 hypertension. 
Two other patients had toxicities not related to bevacizumab. 
One patient, with a previous history of hiatus hernia and 
dyspeptic symptoms, had grade 3 upper abdominal pain in the
absence of gastro-intestinal perforation. The second patient had 
an infected seroma at the primary surgical site, which was 
subsequently found to be due to a local recurrence. 
Importantly, a SUSAR was identified in the bevacizumab arm. A 
48-year old man presented with right eye pain and loss of vision 
on day 11 after his first cycle of bevacizumab; by day 18, he 
had lost all sight in that eye. Ophthalmology review on day 19 
suggested optic neuritis. No other neurological symptoms were 
present and there was no history of demyelinating diseases. CT 
and MRI of head were normal. Posterior leukoencephalopathy 
syndrome was not identified, and no cases of bevacizumab-
related optic neuritis have been previously reported in the 
literature. The patient was withdrawn from treatment and has 
regained some vision. Long-term ophthalmology follow-up has 
been arranged for this patient. 
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Discussion 
A 12-month safety review of the AVAST-M trial suggests that 
adjuvant bevacizumab is very well tolerated in patients with 
completely resected cutaneous malignant melanoma. The 
translational component of this trial could also potentially 
identify potential biomarkers of minimal residual disease, 
predictive markers for bevacizumab response, as well as 
identifying markers of disease relapse. 
We would like to increase the profile and recruitment of patients 
onto this trial in the wider international oncology community. We 
would like to hear from interested cancer physicians if they wish 
to participate in AVAST-M by contacting the oncology trials 
team at Addenbrooke’s Hospital, Cambridge, by using either of 
the two following e-mail addresses: bhawna.sirohi@ 
addenbrookes.nhs.uk or clare.east@addenbrookes.nhs.uk. 
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